Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma - Courtney, K D; Infante, J R; Lam, E T (J Clin Oncol, 2018)
et al.